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Abstract 
 
Background  
There are recognised gaps between evidence and practice in general practice, a setting 
which provides particular challenges for implementation. We earlier screened clinical 
guideline recommendations to derive a set of ‘high impact’ indicators based upon criteria 
including potential for significant patient benefit, scope for improved practice and amenability 
to measurement using routinely collected data. We aim to evaluate the effectiveness and 
cost-effectiveness of a multifaceted, adaptable intervention package to implement four 
targeted, high impact recommendations in general practice. 
 
Methods/Design 
The research programme Action to Support Practice Implement Research Evidence 
(ASPIRE) includes a pair of pragmatic cluster randomised trials which use a balanced 
incomplete block design. Clusters are general practices in West Yorkshire, United Kingdom 
(UK) recruited using an ‘opt-out’ recruitment process. The intervention package adapted to 
each recommendation includes combinations of audit and feedback, educational outreach 
visits and computerised prompts with embedded behaviour change techniques selected on 
the basis of identified needs and barriers to change. In trial one, practices are randomised to 
adapted interventions targeting either diabetes control or risky prescribing and those in trial 
two to adapted interventions targeting either blood pressure control in patients at risk of 
cardiovascular events or anticoagulation in atrial fibrillation. The respective primary 
endpoints comprise achievement of all recommended target levels of Haemoglobin A1c 
(HbA1c), blood pressure and cholesterol in patients with type 2 diabetes, a composite 
indicator of risky prescribing, achievement of recommended blood pressure targets for 
specific patient groups, and anticoagulation prescribing in patients with atrial fibrillation. We 
are also randomising practices to a fifth, non-intervention control group to further assess 
Hawthorne effects. Outcomes will be assessed using routinely collected data extracted 
eleven months after randomisation. Economic modelling will estimate intervention cost-
effectiveness. A process evaluation involving eight non-trial practices will examine 
intervention delivery, mechanisms of action and unintended consequences. 
 
Discussion  
ASPIRE will provide ‘real world’ evidence about the effects, cost-effectiveness and delivery 
of adapted intervention packages targeting high impact recommendations. By implementing 
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our adaptable intervention package across four distinct clinical topics, and using ‘opt-out’ 
recruitment, our findings will provide evidence of wider generalisability. 
 
Trial Registration 
ISRCTN91989345 assigned 20th February 2015 
 
Keywords  
Primary care; implementation; cluster randomised trial; clinical guidelines; diabetes; 
prescribing; atrial fibrillation 
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Background 
Clinical research can only benefit patient and population health if findings are incorporated 
into routine care. There are widely recognised failures to introduce effective new clinical 
practices quickly enough, consistently use those already proven to be effective, or stop those 
found to be ineffective or even harmful. The gap between evidence and practice is an 
important problem for policy-makers, healthcare systems and research funders because it 
limits the health, social and economic impacts of clinical research [1]. Dissemination of best 
practice is necessary but seldom sufficient by itself to ensure implementation. 
The context of general practice in the United Kingdom (UK) presents particular 
implementation challenges – given limited practice organisational capacity, increasing 
complexity of care, and the dispersed and independent nature of practices. Many 
implementation studies focus on one condition (e.g. depression, back pain). This limits 
generalisability; it is uncertain how an intervention developed for one clinical condition will 
work for another [2, 3]. In 2012, we identified 107 clinical guidelines relevant to general 
practice produced by the National Institute for Health and Care Excellence (NICE) [4].  It is 
impracticable and inefficient to invent an implementation strategy for every new guideline. 
Implementation strategies are required which can be adapted to a range of targeted 
problems and sustainably integrated into available primary care systems and resources [5]. 
Action to Support Practices Implement Research Evidence (ASPIRE) is a research 
programme that aims to develop and evaluate an adaptable intervention package to target 
implementation of ‘high impact’ clinical practice recommendations in general practice. 
ASPIRE comprises five, sequential work packages: 
1. Screening of NICE guidelines and associated quality standards to derive a set of 
‘high impact’ indicators based on: burden of illness; potential for significant patient 
benefit from improved practice; likelihood of cost savings without patient harm; and 
feasibility of measuring change using routinely collected data [4]. 
2. Cross-sectional analysis of patient data to identify high impact recommendations with 
greatest scope for improvement (low adherence) and explore variations in adherence. 
3. Interviews with primary care professionals to explore barriers to and enablers of 
adherence to selected high impact recommendations, matching of behaviour change 
techniques to identified barriers and enablers, and development of an adaptable 
intervention package (based on audit and feedback, outreach educational visits and 
computerised prompts). 
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4. Evaluation of the effectiveness and cost-effectiveness of the adapted intervention 
package in targeting the implementation of high impact recommendations. 
5. Conduct of a parallel process evaluation to examine intervention delivery, 
mechanisms of action and unintended consequences. 
This protocol paper describes the randomised evaluation and summarises the process 
evaluation.  
 
Methods/Design  
Study design and setting 
We are conducting a pair of pragmatic cluster randomised trials with general practices as the 
unit of allocation. Cluster randomisation was chosen because the intervention is delivered at 
the practice level and aims to change clinical practice of the whole practice team. Balanced 
incomplete block designs equalise Hawthorne effects whilst maximising power and efficiency 
[6, 7] and also reduce the risk of overburdening practices through exposure to more than one 
intervention. In trial one, practices will be randomised to adapted intervention packages 
targeting either diabetes control or risky prescribing. In trial two, practices will be randomised 
to adapted intervention packages targeting either blood pressure control in patients at high 
risk of cardiovascular events or anticoagulation in atrial fibrillation. The balanced incomplete 
block design has two treatment arms per trial. Within both trials, all intervention packages 
were assumed to be independent in terms of their outcomes and each treatment arm will 
therefore be used as the control arm for the other treatment arm in the same trial. We are 
also including a fifth, non-intervention control group to further assess Hawthorne effects.  
Practices allocated to this arm will not receive any of the ASPIRE interventions, but we will 
examine outcomes via the same routinely collected data. 
The study is set within West Yorkshire, which covers a socioeconomically and ethnically 
diverse population of approximately 2.2 million residents [8] . Around 330 general practices 
are organised within 10 clinical commissioning groups (CCGs), which have roles including 
the purchasing of specialist services and improving quality of primary care.   
 
Participants 
General practices are eligible if they used the SystmOne™ computerised clinical system 
(TPP, http://www.tpp-uk.com/). Approximately two-thirds of West Yorkshire practices use 
SystmOne. The use of a single system simplifies the process of data extraction and of 
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implementing software support. We will exclude practices which had been involved in earlier 
stages of intervention development and piloting. We will also exclude practices in one CCG 
from trial two involved in a concurrent initiative addressing anticoagulation in atrial fibrillation. 
 
 
Recruitment and consent  
Following consultations with our Programme Steering Group, our Public and Patient 
Involvement Panel and all 10 CCGs, we will use an ‘opt out’ approach to recruit and consent 
general practices. Apart from facilitating the recruitment process, we judge that opt-out 
recruitment will enhance pragmatism and hence generalisability by resembling recruitment 
processes typically used by routine quality improvement initiatives [9]. We will send all 
eligible practices an invitation and information sheet via email. This outlines the purpose of 
the trial and what involvement entails, and states that practices will be included unless they 
indicate otherwise. We will follow this with a duplicate pack (including a Freepost return 
envelope to return the opt-out notification) sent via recorded postal delivery. After two weeks, 
we will send reminders by both email and recorded postal delivery to all non-responding 
practices. Four weeks post-initial invitation, we will consider all practices which have not 
opted-out to have consented to participate. Patient-level consent is not required as all 
patient-level data are anonymised. 
 
Intervention 
We broadly conceptualise the implementation intervention as comprising a range of 
behaviour change techniques (e.g. social comparison, information on health consequences, 
action planning). These will be embedded within a package based around three delivery 
mechanisms that possess a known evidence base and are increasingly central to routine 
implementation activities [7]: audit and feedback [7, 10], educational outreach visits [7, 11] 
and computerised prompts [7, 12]. We have further developed the packages iteratively 
through a series of exchanges with our professional and patient advisory groups and piloting 
in five general practices. 
 
Following earlier work and consultations with professional and patient advisory groups, we 
decided to target the implementation of four high impact indicators: 
• Control of HbA1c, blood pressure, and cholesterol in type 2 diabetes [13, 14] 
• Risky prescribing, largely focusing on avoiding adverse effects of non-steroidal anti-
inflammatory drugs (NSAIDs) and anti-platelet drugs [15] 
• Control of blood pressure in people at high risk of cardiovascular events [16]; and 
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• Anticoagulation in people with atrial fibrillation [17] 
 
We conducted semi-structured interviews with primary care professionals based on the 
Theoretical Domains Framework [18] to explore barriers and enablers to achieving the above 
indicators. For each indicator, we matched behaviour change techniques targeting clinicians 
to the most salient barriers and enablers and embedded them within intervention packages. 
 
In brief, the audit and feedback component will comprise quarterly reports individualised for 
each practice and presenting their performance against targeted clinical indicators, together 
with motivational messages based on key theoretical domains identified by our qualitative 
research. The educational outreach visits will be delivered by trained pharmacist facilitators, 
and involve discussion of practice performance and development of action plans. The 
computerised support will include modified versions of the searches used to prepare the 
audit reports and, for risky prescribing only, automated messages triggered by potentially 
risky prescribing combinations. We will also offer practices up to two days of additional 
pharmacist support. The nature of this support will be decided in discussion with practice but 
can include review of patient notes or modification of computerised searches to identify 
specific patient groups to invite for consultation. All practices in the intervention arms will be 
sent electronic and postal copies of the feedback reports. They will also be offered 
educational outreach, additional pharmacist support, searches to identify patients, and, 
where applicable, computerised prompts. Given the pragmatic nature of these trials, the 
acceptance and engagement with all components is optional. We will further describe 
intervention development and content in a separate paper. 
 
 
Outcomes 
The primary endpoints for each intervention package are: 
• The proportion of patients with type 2 diabetes achieving all three of the following 
treatment targets: blood pressure below 140/80 mmHg (or 130/80 mmHg if there is 
kidney, eye or cerebrovascular damage), HbA1c value below or equal to 59 
mmol/mol, and cholesterol level below or equal to 4.0 mmol/l (Trial 1); 
• A composite measure of nine indicators of high-risk NSAID and anti-platelet 
prescribing: prescribing a traditional oral NSAID or low-dose aspirin in patients with a 
history of peptic ulceration without co-prescription of gastro-protection; prescribing a 
traditional oral NSAID in patients aged 75 years or over without co-prescription of 
gastro-protection; prescribing of a traditional oral NSAID and aspirin in patients aged 
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65 years or over without co-prescription of gastro-protection; prescribing of aspirin 
and clopidogrel in patients aged 65 years or over without co-prescription of gastro-
protection; prescribing of warfarin and a traditional oral NSAID; prescribing of warfarin 
and low-dose aspirin or clopidogrel without co-prescription of gastro-protection; 
prescribing an oral NSAID in patients with heart failure; prescribing an oral NSAID in 
patients prescribed both a diuretic and an Angiotensin-Converting-Enzyme Inhibitor 
(ACE-I) or Angiotensin Receptor Blocker (ARB); and, prescribing an oral NSAID in 
patients with chronic kidney disease (CKD; Trial 1); 
• The proportion of patients with satisfactorily controlled blood pressure according to 
recommended targets: under 140/90 mmHg in patients aged under 80 years with 
hypertension; under 150/90 mmHg in patients aged 80 years and over with 
hypertension; under 140/80 mmHg in patients aged under 80 years with diabetes, 
under 130/80mmHg if there are complications of diabetes; under 130/80 mmHg in 
patients aged under 80 years with chronic kidney disease and proteinuria; under 
140/90 mmHg in patients aged under 80 years with coronary heart disease; under 
140/90 mmHg in patients aged under 80 years with peripheral arterial disease; under 
140/90 mmHg in patients aged under 80 years with a history of stroke/transient 
ischemic attack; and, under 140/90 mmHg in patients aged under 80 years with a 
cardiovascular disease risk of 20% or higher (Trial 2); and 
• A composite of the proportion of men with atrial fibrillation and a CHA2DS2-VASc 
score of one prescribed anticoagulation therapy and the proportion of all people with 
atrial fibrillation and a CHA2DS2-VASc score of 2 or above prescribed anticoagulation 
therapy (Trial 2). 
Secondary endpoints comprise: 
• The effects on separate individual indicators that contribute to composite outcomes 
(e.g. individual blood pressure, HbA1c and cholesterol targets in patients with 
diabetes) 
• The effects on recorded processes of care (the proportion of patients with type 2 
diabetes achieving all nine of the following recommended processes of care in the 
previous 12 months: blood pressure recording, HbA1c recording, total cholesterol 
recording, urine albumin: creatinine ratio (ACR) or protein: creatinine ratio (PCR)] or 
proteinuria coding, estimated glomerular filtration rate (eGFR] or serum creatinine 
testing, foot care review, retinal screening, body mass index recording, smoking 
status). 
• The effects on continuous intermediate clinical outcomes (i.e. value of last recorded 
blood pressure, HbA1c, cholesterol). 
10 
	
 
In addition, we will gather selected data from the Quality Outcomes Framework (QOF 2015-
16 indicator list (Table 1). The QOF is a performance management system whereby general 
practices are remunerated according to achievement of targets reflecting quality of care 
across four domains of clinical, organisational, patient experience and additional services 
[19]. Practice data collection for QOF operates on an annual cyclical basis from 1st April to 
31st March. Several indicators map onto our trial recommendations (Table 1). We have also 
selected a series of non-trial related indicators that represent different aspects of care and 
service delivery. These will be used to measure unintended impacts on quality of care and 
relate to four areas: coronary heart disease (an example of a long-term, physical condition), 
mental health (long-term, non-physical), smoking (health promotion), and asthma (long-term, 
physical condition).  
All outcomes will be assessed at eleven months following randomisation. Ideally, we would 
have preferred a 12-month follow up period but this will not be feasible given our intention to 
stratify randomisation according to pre-intervention outcome adherence and to deliver the 
interventions to coincide with the annual QOF cycle. The pre-intervention adherence data will 
not be available until the end of the previous QOF cycle and will take a month to check and 
analyse before randomisation can occur. 
 
Data collection  
Primary and secondary endpoints 
We will use anonymised patient health records, extracted remotely from participating 
practices to obtain data on indicator adherence. The data will be collected via the Data 
Quality Team at the National Health Service (NHS) Yorkshire & Humber Commissioning 
Support Unit. Data extraction and collation procedures are performed under the appropriate 
Information Governance Guidance, in line with Caldicott Principles. 
  
Data queries are developed by mapping inclusion and exclusion criteria to the numerators 
and denominators for each indicator and building the search within SystmOne. Reports are 
generated by a data analyst to define output for each indicator numerator and denominator 
and extracted in a standardised format. The outputs are anonymised and checked for 
accuracy prior to transfer to the Leeds Institute of Clinical Trials Research (LICTR) via a 
Secure File Transfer system.  
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Pre-intervention data will be extracted for randomisation stratification and then continue 
quarterly to inform the content of feedback reports. The final extraction will be used for 
endpoint analysis.  
 
Practice and patient characteristics  
Data on practice characteristics will be obtained from publicly available sources 
(http://www.hscic.gov.uk) and include: practice list size (number of registered patients), 
number of general practitioner (GP) partners, number of salaried GPs, practice teaching 
status, practice level Index of Multiple Deprivation (IMD), ethnic profile of practice register, 
achievement of QOF indicators, patient satisfaction (proportion who would recommend 
practice to others), patient-rated practice accessibility (proportion able to speak with GP or 
nurse within 48 hours of approach), and practice prescribing costs. Patient characteristics will 
be extracted alongside adherence data and include: age, sex, comorbidity (number of QOF 
disease registers patient is included in) and polypharmacy (number of repeat prescriptions). 
 
Intervention fidelity 
Intervention delivery and fidelity will be monitored throughout the trials. Structured logs 
record the number of outreach sessions delivered, number of staff attending, whether 
feedback reports were i) received, and ii) used, as well as any additional support requested 
by the practice. Outreach facilitators will complete standard review forms following each visit. 
Reasons for declining an outreach visit will also be documented. We will collect data on 
which practices accept the invitation to join indicator-specific SystmOne organisational 
groups. Acceptance is required in order to access the searches, as well as any available 
computer protocols. These lists will be monitored during the trials and reminders sent to 
practices which have not joined. 
 
Sample size  
Data collected for the second ASPIRE work package (cross-sectional assessment in a 
random sample of practices of adherence to selected clinical indicators) was used to 
estimate mean cluster size (number of targeted patients per practice by indicator), coefficient 
of variation, intra-cluster correlation coefficient and control group achievement rates (Table 
2).  Depending on the recommendation, assumed intracluster correlation coefficients (ICC) 
ranged from 0.03 to 0.06, mean cluster sizes from 55 to 800 and the coefficient of variation of 
cluster sizes from 0.6 to 0.79 (Table 2). The median effect sizes on processes and outcomes 
of care for a range of single interventions in guideline implementation studies are around 4-
9% [20, 21]. Given the enhancements we are making to the intervention packages and that 
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we are targeting recommendations with greater scope for improvement [10], we judge that an 
estimated effect size of 15% for outcomes related to diabetes, hypertension and atrial 
fibrillation are realistic and clinically relevant. Control group adherence rates in risky 
prescribing are considerably higher (Table 1), and considering a potential ceiling effect, we 
estimated 5% to be a realistic and clinically relevant effect size for this intervention. 
In order to achieve  90% power, and allowing for an alpha error rate of 2.5% (to adjust for 
two outcome comparisons in each trial) and a 10% drop-out rate, we require 40 clusters per 
arm in trial 1 (diabetes and risky prescribing) and 32 clusters per arm in trial 2 (hypertension 
and atrial fibrillation). We therefore aim to recruit 144 practices (Table 3). We allowed for the 
possibility of a fifth arm because we anticipated achieving above-target recruitment levels 
using the opt-out approach. 
 
Randomisation 
Randomisation will be conducted using a computer-generated minimisation programme 
(incorporating a random element) to ensure arms are balanced. It will follow a two-stage 
process. First, practices will be stratified by CCG and practice list size (defined as 
above/below the West Yorkshire median list size of 6562 patients) and then randomised to 
Trial 1, Trial 2, or the no-intervention arm. Second, practices in Trials 1 and 2 will then be 
stratified again by CCG, practice list size and pre-intervention adherence to the two relevant 
targeted clinical areas. They will then be randomised to the individual arms within each trial. 
Cluster randomisation will be performed at LICTR by the trial statistician. 
For both trials, each practice will act as a control practice for the other corresponding arm in 
the trial to which they are randomised.  Practices in the no intervention arm will operate as 
additional controls. 
 
 
Statistical analysis 
All analyses and data summaries will be conducted on the intention-to-treat (ITT) population, 
defined as all randomised practices regardless of compliance with the intervention or 
withdrawal from the study. No formal interim analyses are planned, and final analysis will 
take place when all available data are received from the final extract. 
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Primary analysis 
As the trials are cluster randomised, the primary outcome measures (levels of adherence to 
the four indicators) will be compared between the intervention and control groups using two-
level binary logistic models, with patients nested within general practices. Effect sizes and 
95% confidence intervals will be reported. 
 
Secondary analyses 
Secondary analyses will be undertaken using both binary and continuous outcome data (e.g. 
blood pressure levels). For binary outcome data we will also be using two-level binary logistic 
models; for continuous data two-level linear models. Effect sizes and 95% confidence 
intervals will be reported. 
 
 
Cost-effectiveness analysis 
We plan to conduct economic analyses for three of the four intervention packages: diabetes 
control, risky prescribing and blood pressure control. We had to limit the number of outcomes 
modelled because of our limited resources and selected three based on availability of 
existing models.  
Economic modelling has the primary objective of identifying the interventions’ incremental 
cost-effectiveness ratios. In order to assess the impact of the intervention over a lifetime 
horizon, longer-term models will be developed for each of the three selected areas. The 
decision analytic models will be informed by published evidence on costs (taking a UK health 
and social care perspective as per NICE guidelines) and utility values (used to construct 
Quality-adjusted Life Years [QALYs]). Values generated for time periods greater than 12 
months will be discounted at the 3.5% rate. 
The economic evaluations will make use of an adherence parameter informed by 
effectiveness data obtained from the study. The parameter will reflect the impact of the 
intervention; for example, an improvement in adherence should lead to an improvement in 
outcomes (QALYs) predicted by the model. 
The value of the intervention will depend upon the value of the behaviour it promotes. Thus, 
its cost-effectiveness will be application-specific, just as drugs which treat multiple conditions 
do not have a single cost-effectiveness. The main outcome of interest will be cost per QALY 
and net monetary benefit. We will conduct extensive deterministic sensitivity analysis and 
probabilistic sensitivity analysis to assess uncertainty surrounding estimates of cost-
effectiveness. 
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Trial and data monitoring 
Trial supervision includes a core project team, a Trial Management Group (TMG; consisting 
of a subset of the project team and relevant independent experts in statistics and health 
economics) and an independent Trial Steering Committee (TSC). For a trial of this nature 
and duration, a separate Data Monitoring and Ethics Committee is not required. Rather, the 
TSC will adopt a safety monitoring role, with the constitution of a sub-committee to review 
safety issues where this becomes necessary. Any clinical governance issues pertaining to 
aspects of routine management will be brought to the attention of the TSC and, where 
applicable, to individual practices.  
 
 
Process evaluation 
We will conduct a process evaluation alongside the trials to: 
• Describe how the intervention packages are implemented and the extent to which 
they become embedded in routine systems and practice 
• Explore whether the interventions worked as predicted or by an alternative means; 
and 
• Identify unintended consequences of the delivery and implementation of the 
intervention packages in practice 
 
Recruitment and consent 
We will recruit a subset of general practices not involved in the trials. Email invitations will be 
followed up by telephone calls and practice-level informed consent obtained. Practices will 
be reimbursed for their time and commitment over the study period. 
We aim to recruit eight practices, providing a sample of two practices per clinical topic. We 
will purposively select practices to ensure a spread across CCGs and a range of practice 
sizes (patient list size and number of practice staff). Where individual practice staff members 
participate in audio-recorded interviews, individual written consent will be obtained. 
 
Method 
Process evaluation practices will be randomised by the trial statistician to receive an 
intervention package targeting one of the four indicators. These will be delivered in identical 
fashion to, and in parallel with, the trial practices. 
In preparation for data collection at the process evaluation practices, we will develop a logic 
model to capture how we expect the intervention package and its constituent components to 
be received and how it may bring about change [27, 28]. 
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Throughout the intervention period, we will conduct in-depth work with process evaluation 
practices to observe and monitor how the interventions are received and implemented. Data 
collection will proceed via observations, interviews and the collection of administrative data 
[29]. 
• Observations: where possible, settings where practice staff discuss or interact with 
the intervention package and/or clinical topic will be observed (e.g. educational 
outreach sessions, practice meetings), and detailed field notes generated to capture 
how staff receive and interact with the intervention package at a group level [30]. No 
individual patient consultations or data will be collected. 
• Interviews: staff will be interviewed individually about their role in the practice, their 
interaction with the intervention, whether it is perceived to influence behaviour in 
relation to the clinical topic, if and how the intervention has been incorporated into 
routine practice, and any unintended consequences arising from the intervention. 
Interviews will be both semi-structured and open-ended to help capture intended and 
unintended mechanisms. A range of practice staff will be interviewed in each 
participating practice (up to 12 individuals per site), including staff with administrative, 
clinical and managerial roles. Interviews will take place at three time points, twice to 
coincide with delivery of key intervention components (educational outreach and 
feedback report delivery), and finally, after trial end. Interviews will be audio-recorded 
and transcribed verbatim. 
• Administrative data: information relating to the intervention package and/or target 
clinical recommendations will be collected. Examples include meeting minutes, 
practice protocols around a clinical topic, and communications (e.g. emails) about the 
clinical topic or intervention package. 
 
Analysis 
Data will be collated to produce chronological reconstructions of the process and outcomes 
of receiving and implementing the intervention package. This will be on a case by case basis, 
wherein each practice acts as a case study [31]. Data will be analysed using a framework 
approach [32] based on our pre-specified theories of how the intervention package will work 
(outlined in the logic model) and drawing on normalisation process theory to understand the 
process of implementation in each practice [33]. We also aim to identify and explore any 
unintended consequences and mechanisms of the intervention package during analysis. 
 
Ethical review 
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Ethical approval has been obtained through the UK National Research Ethics Service 
(14/SC/1393). NHS Research and Development approvals were granted by the NHS 
Yorkshire & Humber Commissioning Support Unit on behalf of all the CCGs in West 
Yorkshire (approved 30th January, 2015). 
 
Trial status 
The trials are currently in progress. No endpoint data collection nor cleaning has yet 
occurred.  
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Tables and figures 
 
Table 1. List of indicators from the Quality and Outcomes Framework 2015-16 included 
in the ASPIRE analysis 
Domain QOF 
indicator 
number 
(2015-16) 
Indicator 
Atrial fibrillation AF006 The percentage of patients with atrial fibrillation in whom 
stroke risk has been assessed using the CHA2DS2-VASc 
score risk stratification scoring system in the preceding 12 
months (excluding those patients with a previous 
CHADS2 or CHA2DS2- VASc score of 2 or more). 
Atrial fibrillation AF007 In those patients with atrial fibrillation with a record of a 
CHA2DS2-VASc score of 2 or more, the percentage of 
patients who are currently treated with anticoagulation 
drug therapy. 
Secondary 
prevention of 
coronary heart 
disease 
CHD002 The percentage of patients with coronary heart disease in 
whom the last blood pressure reading (measured in the 
preceding 12 months) is 150/90 mmHg or less. 
Secondary 
prevention of 
coronary heart 
disease 
CHD005 The percentage of patients with coronary heart disease 
with a record in the preceding 12 months that aspirin, an 
alternative anti-platelet therapy, or an anti-coagulant is 
being taken. 
Secondary 
prevention of 
coronary heart 
disease 
CHD007 The percentage of patients with coronary heart disease 
who have had influenza immunisation in the preceding 1 
August to 31 March. 
Hypertension HYP006 The percentage of patients with hypertension in whom the 
last blood pressure reading (measured in the preceding 
12 months) is 150/90 mmHg or less. 
Stroke and 
transient 
ischemic attack 
STIA003 The percentage of patients with a history of stroke or TIA 
in whom the last blood pressure reading (measured in the 
preceding 12 months) is 150/90 mmHg or less. 
Diabetes 
mellitus 
DM002 The percentage of patients with diabetes, on the register, 
in whom the last blood pressure reading (measured in the 
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preceding 12 months) is 150/90 mmHg or less. 
Diabetes 
mellitus 
DM003 The percentage of patients with diabetes, on the register, 
in whom the last blood pressure reading (measured in the 
preceding 12 months) is 140/80 mmHg or less. 
Diabetes 
mellitus 
DM004 The percentage of patients with diabetes, on the register, 
whose last measured total cholesterol (measured within 
the preceding 12 months) is 5 mmol/l or less. 
Diabetes 
mellitus 
DM006 The percentage of patients with diabetes, on the register, 
with a diagnosis of nephropathy (clinical proteinuria) or 
micro-albuminuria who are currently treated with ACE-I (or 
ARBs). 
Diabetes 
mellitus 
DM007 The percentage of patients with diabetes, on the register, 
in whom the last IFCC-HbA1c is 59 mmol/mol or less in 
the preceding 12 months. 
Diabetes 
mellitus 
DM008 The percentage of patients with diabetes, on the register, 
in whom the last IFCC-HbA1c is 64 mmol/mol or less in 
the preceding 12 months. 
Diabetes 
mellitus 
DM009 The percentage of patients with diabetes, on the register, 
in whom the last IFCC-HbA1c is 75 mmol/mol or less in 
the preceding 12 months. 
Diabetes 
mellitus 
DM0012 The percentage of patients with diabetes, on the register, 
with a record of a foot examination and risk classification: 
1) low risk (normal sensation, palpable pulses), 2) 
increased risk (neuropathy or absent pulses), 3) high risk 
(neuropathy or absent pulses plus deformity or skin 
changes in previous ulcer) or 4) ulcerated foot within the 
preceding 12 months. 
Diabetes 
mellitus 
DM0014 The percentage of patients newly diagnosed with 
diabetes, on the register, in preceding 1 April to 31 March 
who have a record of being referred to a structured 
education programme within 9 months after entry on to 
the diabetes register 
Diabetes 
mellitus 
DM0018 The percentage of patients with diabetes, on the register, 
who have had influenza immunisation in the preceding 1 
August to 31 March. 
Mental health MH002 The percentage of patients with schizophrenia, bipolar 
affective disorder and other psychoses who have a 
comprehensive care plan documented in the record, in the 
preceding 12 months, agreed between individuals, their 
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family and/or carers as appropriate. 
Mental health MH003 The percentage of patients with schizophrenia, bipolar 
affective disorder and other psychoses who have a record 
of blood pressure in the preceding 12 months. 
Smoking SMOK002 The percentage of patients with any or any combination of 
the following conditions: coronary heart disease (CHD), 
peripheral arterial disease (PAD), stroke or transient 
ischemic attack (TIA), hypertension, diabetes, chronic 
obstructive pulmonary disease (COPD), chronic kidney 
disease (CKD), asthma, schizophrenia, bipolar affective 
disorder or other psychoses whose notes record smoking 
status in the preceding 12 months. 
Smoking SMOK004 The percentage of patients aged 15 or over who are 
recorded as current smokers who have a record of an 
offer or support and treatment within the preceding 24 
months. 
Smoking SMOK005 The percentage of patients with any or any combination of 
the following conditions: CHD, PAD, stroke or TIA, 
hypertension, diabetes, COPD, CKD, asthma, 
schizophrenia, bipolar affective disorder or other 
psychoses who are recorded as current smokers who 
have a record of an offer of support and treatment within 
the preceding 12 months 
Asthma AST003 The percentage of patients with asthma, on the register, 
who have had an asthma review in the preceding 12 
months that includes an assessment of asthma control 
using the 3 Royal College of Physician questions. 
 
 
Table 2. Key sample size assumptions 
 
Atrial 
fibrillation 
Blood pressure 
control 
Risky 
prescribing 
Diabetes 
control 
Mean number of patients per 
practice (cluster size) 
55 800 420 280 
Coefficient of variation (CV) 
of cluster size 
0.79 0.67 0.65 0.6 
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Intra-cluster correlation 
coefficient (ICC) 
0.06 0.06 0.03 0.06 
Control group adherence 0.6 0.72 0.89 0.43 
 
 
 
Table 3. Trial design & number of practices required 
Trial 1 Trial 2 
Non-intervention control Diabetes 
control 
Risky 
prescribing 
Blood 
pressure 
control 
Anticoagulation 
in atrial 
fibrillation 
40 40 32 32 
[number dependent on 
recruitment beyond that 
required for intervention 
sample] 
	
